amitriptyline + fluvoxamine

Amitriptyline + fluvoxamine is a combination of two antidepressant medications used together, primarily in the treatment of major depressive disorder. Amitriptyline is a tricyclic antidepressant (TCA) that inhibits the reuptake of norepinephrine and serotonin, increasing their levels in the synaptic cleft. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that selectively inhibits serotonin reuptake, thereby increasing serotonergic activity in the central nervous system. The combination may be considered for patients with depression who do not respond to monotherapy; however, it carries an increased risk of pharmacokinetic interactions due to fluvoxamine’s inhibition of cytochrome P450 enzymes responsible for metabolizing amitriptyline. This can lead to elevated plasma concentrations of amitriptyline and its metabolites, potentially enhancing both therapeutic effects and adverse reactions such as anticholinergic side effects or cardiac arrhythmias. Clinical studies suggest this combination can result in more rapid or robust antidepressant response but requires careful monitoring for toxicity and signs of serotonin syndrome[1][2][3][4].